Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M |
Open | High | Low | Value | Volume |
$1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5700 | $1.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.45 | 591 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 5700 | 1.430 |
3 | 13542 | 1.420 |
2 | 20700 | 1.410 |
1 | 3500 | 1.405 |
6 | 25737 | 1.400 |
Price($) | Vol. | No. |
---|---|---|
1.450 | 591 | 1 |
1.500 | 7000 | 1 |
1.510 | 2408 | 1 |
1.540 | 10000 | 1 |
1.550 | 26171 | 3 |
Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.46 |
  |
Change
-0.005 ( 0.23 %) |
|||
Open | High | Low | Volume | ||
$1.44 | $1.49 | $1.43 | 9034 | ||
Last updated 13.08pm 24/05/2024 ? |
Featured News
RAC (ASX) Chart |